Viewing Study NCT01202175



Ignite Creation Date: 2024-05-05 @ 10:51 PM
Last Modification Date: 2024-10-26 @ 10:25 AM
Study NCT ID: NCT01202175
Status: COMPLETED
Last Update Posted: 2019-08-21
First Post: 2010-06-24

Brief Title: Effects of the Beta-blocker Nebivolol Bystolic on Subjects With High Normal Blood Pressure andor a Family History of Hypertension
Sponsor: University of California San Diego
Organization: University of California San Diego

Study Overview

Official Title: Effects of the Novel Beta-adrenergic Antagonist Nebivolol Bystolic on Prehypertensive Subjects at Genetic Risk of Hypertension Implications for Inflammation Endothelial Dysfunction and Oxidative Stress
Status: COMPLETED
Status Verified Date: 2019-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The investigators aim to evaluate subjects at high risk of future development of hypertension those with a family history of hypertension andor that already have high normalSBP 120-139 mmHg or DBP 80-89 mmHg blood pressure The investigators plan to investigate whether these subjects have the same markers such as microscopic protein in the urine or C-reactive protein in the blood in the blood and urine that people with high blood pressure have and whether they are improved before and after taking the beta-blocker nebivolol
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None